Introduction:
The pharmaceutical industry is a critical driver of both public health outcomes and economic growth. India has emerged as a major pharmaceutical producer, combining technological advancement with socially significant contributions to healthcare.
India in the Global Pharmaceuticals Market:
Known as the “Pharmacy of the World,” India is preferred globally for its affordable pricing and assured quality.
-
- Global Standing: India ranks 3rd globally by volume and 11th by value, with over 3,000 companies and 10,500 manufacturing units.
- Market Growth: The domestic market is valued at USD 60 billion and is projected to reach USD 130 billion by 2030.
- Generic Powerhouse: India is the largest global supplier of generic medicines, accounting for 20% of global supply across 60 therapeutic categories.
- USFDA Approvals: India hosts the highest number of USFDA-approved manufacturing plants outside the United States, reinforcing international trust.
Global Reach and Investment:
India’s export-driven growth is underpinned by its critical role in global health networks.
-
- Vaccine Leadership: Indian manufacturers meet 40–70% of global demand for DPT and BCG vaccines and account for 90% of the WHO’s measles vaccine demand.
- Export Value: In 2024–25, pharmaceutical exports stood at USD 30.5 billion, reaching 191 countries. Approximately 50% of these exports are directed to highly regulated markets in the U.S. and Europe.
- Medical Devices: Exports in this segment grew from USD 2.5 billion in 2020–21 to USD 4.1 billion in 2024–25.
- Foreign Direct Investment (FDI): The sector is a top-10 industry for FDI, with flows reaching ₹13,193 crore in FY26 (up to September).
Strengthening Exports through Trade Agreements:
Recent trade agreements are designed to deepen India’s integration into global healthcare value chains.
| Agreement | Key Impact on Pharmaceuticals and Medical Devices |
| India-EU FTA | Expands market access to an EU market valued at approx. USD 572.3 billion. |
| India-UK CETA | Provides zero-duty access for 56 pharmaceutical tariff lines and various medical devices. |
| India-NZ FTA | Grants zero-duty access to pharmaceutical products across approximately 90 tariff lines. |
Government Interventions and Production Linked Incentive (PLI) Schemes:
PLI schemes are the cornerstone of efforts to reduce import dependence and boost domestic manufacturing.
1. PLI for Pharmaceuticals
-
- Focus: High-value biopharmaceuticals, complex generics, and autoimmune drugs.
- Sales & Exports: Total sales reached ₹3,16,797 crore (up to September 2025), with exports accounting for ₹2,03,730 crore.
- Employment: Approximately 97,000 persons have been employed under this scheme.
2. PLI for Bulk Drugs (APIs/KSMs/DIs)
-
- Established Capacity: Manufacturing capacity of 55,100 metric tonnes per year has been created for 26 critical inputs.
- Import Avoidance: PLI schemes have already helped avoid imports worth ₹3,591 crore.
3. PLI for Medical Devices
-
- Performance: Attracted an actual investment of ₹1,093.69 crore with cumulative sales of ₹12,344.37 crore.
Infrastructure and Innovation Initiatives:
To further strengthen the ecosystem, the government is investing in specialized parks and research.
-
- Bulk Drug Parks: Three parks are under development in Andhra Pradesh, Gujarat, and Himachal Pradesh with a total project cost exceeding ₹6,306.68 crore.
- Medical Devices Parks: Three parks are being established in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu.
- Biopharma SHAKTI: Launched in the Union Budget 2026–27 with a ₹10,000 crore outlay to build an ecosystem for domestic production of biologics and biosimilars. It includes establishing 3 new NIPERs and creating 1,000 accredited clinical trial sites.
- Affordability (PMBJP): Over 18,646 Jan Aushadhi Kendras are operational as of February 2026, providing quality generic medicines and sanitary napkins at highly subsidized rates.
Governance and Regulation:
India’s pharmaceutical system is anchored by a robust regulatory framework.
-
- CDSCO: The national authority overseeing new drug approvals and clinical trials to ensure safety and quality.
- NPPA: Responsible for fixing and revising drug prices to ensure the availability of essential medicines.
- IPC: Manages the Indian Pharmacopoeia, a compendium of drug standards recognized in 19 countries.
Challenges:
-
- Reliance on Raw Materials: Despite PLI successes, a significant portion of Key Starting Materials (KSMs) and Drug Intermediates still rely on imports from a single dominant source, posing a supply chain risk.
- R&D Intensity: While India leads in generic volume, transitioning to innovation-led growth (new chemical entities) requires substantially higher R&D investment compared to the current industry average.
- Regulatory Compliance: Maintaining the highest quality standards across 10,500 units is a massive undertaking; any compliance failure at a major unit can impact the “India Brand” globally.
- Pricing Pressures: Global competition in the generic market and strict domestic price controls by the NPPA can limit the profit margins available for reinvestment into high-end research.
Way Forward:
-
- NIPER Upgradation: Strengthening the institutional network by establishing 3 new NIPERs and upgrading 7 existing ones to create a specialized workforce.
- Clinical Trial Expansion: Developing a network of over 1,000 accredited clinical trial sites to support the discovery of new therapies.
- Market Diversification: Strategically expanding exports to emerging destinations like Nigeria, Mexico, Brazil, and Saudi Arabia to mitigate regional tariff risks.
- Generic-to-Innovation Pivot: Leveraging the PRIP scheme to move beyond generic manufacturing toward precision medicine and novel medical devices.
Conclusion:
Through targeted schemes like PLI and Biopharma SHAKTI, along with expanding global trade linkages, India is positioned on a forward-looking trajectory that supports long-term healthcare resilience and economic growth.
Spread the Word
